Relevant bibliographies by topics / PDE5 inhibitors

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'PDE5 inhibitors'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'PDE5 inhibitors.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "PDE5 inhibitors"

1

Bloom, Timothy J. "Cyclic nucleotide phosphodiesterase isozymes expressed in mouse skeletal muscle." Canadian Journal of Physiology and Pharmacology 80, no. 12 (2002): 1132–35. http://dx.doi.org/10.1139/y02-149.

Full text
Abstract:
To understand changes in cyclic nucleotide metabolism in muscle disease states, the expression of phosphodiesterase (PDE) isozymes in normal mouse leg muscle was examined. Four subcellular fractions were generated by differential centrifugation at 10 000 × g and 100 000 × g. cAMP PDE activity was found predominately in the soluble fractions, while cGMP PDE activity was more evenly distributed amongst soluble and particulate fractions. Pharmacological inhibitors demonstrate that PDE4 represents the major cAMP hydrolyzing activity and PDE2 represents the major cGMP hydrolyzing activity in mouse
APA, Harvard, Vancouver, ISO, and other styles
2

Favot, Laure, Thérèse Keravis, Vincent Holl, Alain Bec, and Claire Lugnier. "VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors." Thrombosis and Haemostasis 90, no. 08 (2003): 334–43. http://dx.doi.org/10.1160/th03-02-0084.

Full text
Abstract:
SummaryMigration and proliferation of endothelial cells in response to VEGF play an important role in angiogenesis associated to pathologies such as atherosclerosis, diabetes and tumor development. Elevation of cAMP in endothelial cells has been shown to inhibit growth factor-induced proliferation. Our hypothesis was that inactivation of cAMP-specific phosphodiesterases (PDEs) would inhibit angiogenesis. The purpose of this study was to evaluate the effect of PDE inhibitors on in vitro and in vivo angiogenesis, using human umbilical vein endothelial cell (HUVEC) and chick chorioallantoic membr
APA, Harvard, Vancouver, ISO, and other styles
3

Temkitthawon, Prapapan, Kanokwan Changwichit, Nantaka Khorana, Jarupa Viyoch, Khanit Suwanborirux, and Kornkanok Ingkaninan. "Phenanthrenes from Eulophia macrobulbon as Novel Phosphodiesterase-5 Inhibitors." Natural Product Communications 12, no. 1 (2017): 1934578X1701200. http://dx.doi.org/10.1177/1934578x1701200121.

Full text
Abstract:
Phosphodiesterase 5 (PDE5) inhibitors can be used for the treatment of erectile dysfunction and pulmonary hypertension. In order to search for new leads of PDE5 inhibitors, we investigated the chemical constituents of the tubers of Eulophia macrobulbon (E.C. Parish & Rchb. f) Hook. f A new phenanthrene, 9,10-dihydro-4-(4′-hydroxybenzyl)-2,5-dimethoxyphenanthrene-1,7-diol (1) and three known phenanthrenes i.e., 1-(4′-hydroxybenzyl)-4,8-dimethoxyphenanthrene-2,7-diol (2), (9,10-dihydro-2,5-dimethoxyphenanthrene-1,7-diol (3) and 1,5,7-trimethoxyphenanthrene-2,6-diol) (4) were isolated. Among
APA, Harvard, Vancouver, ISO, and other styles
4

Sarfati, Marika, Véronique Mateo, Sylvie Baudet, et al. "Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells." Blood 101, no. 1 (2003): 265–69. http://dx.doi.org/10.1182/blood-2002-01-0075.

Full text
Abstract:
Abstract Type 4 phosphodiesterase (PDE4) inhibitors reportedly induce apoptosis in chronic lymphocytic leukemia (CLL) cells. Following clinical improvement of one previously untreated CLL patient with sildenafil therapy, we evaluated the in vitro induction of apoptosis in CLL cells by 4 PDE5/6 inhibitors, including sildenafil, vardenafil, zaprinast, and methoxyquinazoline (MQZ). After 24 hours of culture, the various PDE inhibitors differed in their ability to induce apoptosis, with zaprinast displaying no killing effect. Normal B cells isolated from control donors were totally resistant to PD
APA, Harvard, Vancouver, ISO, and other styles
5

Germain, Nöella, Elisabeth Boichot, Jean-Michel Planquois, and Vincent Lagente. "Reduced Airway Hyperresponsiveness by Phosphodiesterase 3 and 4 Inhibitors in Guinea-Pigs." Mediators of Inflammation 8, no. 3 (1999): 153–57. http://dx.doi.org/10.1080/09629359990487.

Full text
Abstract:
The aim of the present study was to compare the effects of selective phosphodiesterase (PDE) 3, 4 and 5 inhibitors on antigen-induced airway hyperresponsiveness in sensitized guinea-pigs. When the sensitized guinea-pigs were orally pre-treated with the selective PDE4 inhibitor, Ro 20-1724 (30 mg/kg), and studied 48 h after OA, a significant reduction (p<0.01) of the leftward shift of the dose-response curve to ACh was noted, whereas it was ineffective at the lower dose (10 mg/kg). Administration of the selective PDE3 inhibitor, milrinone (30 mg/kg) also elicited a significant reduction (p&l
APA, Harvard, Vancouver, ISO, and other styles
6

DAY, Jonathan P., Julian A. T. DOW, Miles D. HOUSLAY, and Shireen-A. DAVIES. "Cyclic nucleotide phosphodiesterases in Drosophila melanogaster." Biochemical Journal 388, no. 1 (2005): 333–42. http://dx.doi.org/10.1042/bj20050057.

Full text
Abstract:
Cyclic nucleotide PDEs (phosphodiesterases) are important enzymes that regulate intracellular levels of cAMP and cGMP. In the present study, we identify and characterize novel PDEs in the genetic model, Drosophila melanogaster. The Drosophila genome encodes five novel PDE genes in addition to dunce. Predicted PDE sequences of Drosophila show highly conserved critical domains when compared with human PDEs. Thus PDE-encoding genes of D. melanogaster are CG14940-PDE1C, CG8279-PDE6β, CG5411-PDE8A, CG32648-PDE9 and CG10231-PDE11. Reverse transcriptase–PCRs of adult tissues reveal widespread express
APA, Harvard, Vancouver, ISO, and other styles
7

McKenna, Sean D., Michael Pietropaolo, Enrico Gillio Tos, et al. "Pharmacological Inhibition of Phosphodiesterase 4 Triggers Ovulation in Follicle-Stimulating Hormone-Primed Rats." Endocrinology 146, no. 1 (2005): 208–14. http://dx.doi.org/10.1210/en.2004-0562.

Full text
Abstract:
Phosphodiesterases (PDEs) are a family of enzymes that hydrolyze cyclic nucleotides to render them biologically inactive. As such, these enzymes are critical regulators of signal transduction pathways that use cyclic nucleotides as second messengers. PDE4 is one such member that has been identified in ovarian tissue and purported to have a role in the regulation of gonadotropin action. In the present study, selective PDE4 inhibitors enhanced intracellular signaling in a human LH receptor-expressing granulosa cell line. In vivo, PDE4 inhibition in FSH-primed rats resulted in ovulation, indicati
APA, Harvard, Vancouver, ISO, and other styles
8

Wright, Lyndon C., Joachim Seybold, Annette Robichaud, Ian M. Adcock, and Peter J. Barnes. "Phosphodiesterase expression in human epithelial cells." American Journal of Physiology-Lung Cellular and Molecular Physiology 275, no. 4 (1998): L694—L700. http://dx.doi.org/10.1152/ajplung.1998.275.4.l694.

Full text
Abstract:
Epithelial cells play a critical role in airway inflammation and have the capacity to produce many inflammatory mediators, including bioactive lipids and proinflammatory cytokines. Intracellular levels of cAMP and cGMP are important in the control of inflammatory cell function. These cyclic nucleotides are inactivated via a family of phosphodiesterase (PDE) enzymes, providing a possible site for drug intervention in chronic inflammatory conditions. We studied the expression of PDE activity in an epithelial cell line (A549) and in primary human airway epithelial cells (HAECs). We measured PDE f
APA, Harvard, Vancouver, ISO, and other styles
9

Hussein, Abdel Haleem M., Ahmed A. Khames, Abu-Bakr A. El-Adasy, et al. "Multifunctional Isosteric Pyridine Analogs-Based 2-Aminothiazole: Design, Synthesis, and Potential Phosphodiesterase-5 Inhibitory Activity." Molecules 26, no. 4 (2021): 902. http://dx.doi.org/10.3390/molecules26040902.

Full text
Abstract:
The elaboration of new small molecules that target phosphodiesterase enzymes (PDEs), especially those of type 5 (PDE5), is an interesting and emerging topic nowadays. A new series of heterocycle-based aminothiazoles were designed and synthesized from the key intermediate, 3-oxo-N-(thiazol-2-yl)butanamide (a PDE5 inhibitor that retains its amidic function), as an essential pharmacophoric moiety. The PDE5 inhibitors prevent the degradation of cyclic guanosine monophosphate, thereby causing severe hypotension as a marked side effect. Hence, an in vivo testing of the target compounds was conducted
APA, Harvard, Vancouver, ISO, and other styles
10

Tulsian, Nikhil K., Valerie Jia-En Sin, Hwee-Ling Koh, and Ganesh S. Anand. "Development of Phosphodiesterase–Protein-Kinase Complexes as Novel Targets for Discovery of Inhibitors with Enhanced Specificity." International Journal of Molecular Sciences 22, no. 10 (2021): 5242. http://dx.doi.org/10.3390/ijms22105242.

Full text
Abstract:
Phosphodiesterases (PDEs) hydrolyze cyclic nucleotides to modulate multiple signaling events in cells. PDEs are recognized to actively associate with cyclic nucleotide receptors (protein kinases, PKs) in larger macromolecular assemblies referred to as signalosomes. Complexation of PDEs with PKs generates an expanded active site that enhances PDE activity. This facilitates signalosome-associated PDEs to preferentially catalyze active hydrolysis of cyclic nucleotides bound to PKs and aid in signal termination. PDEs are important drug targets, and current strategies for inhibitor discovery are ba
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "PDE5 inhibitors"

1

Wang, Guocheng. "Design, synthesis and development of PDE5 inhibitors." Thesis, Aston University, 2009. http://publications.aston.ac.uk/15405/.

Full text
Abstract:
This research project is concerned with the design, synthesis and development of new phosphodiesterase 5 (PDE5) inhibitors with improved selectivities and lower toxicities. Two series of a 5 member and a 6 member ring fused heterocyclic compounds were designed, and synthesized. By alteration of starting materials and fragments, two virtual libraries, each is consisted of close to hundred compounds, were obtained successfully. The screening of sexual stimulation activity with rabbits demonstrated both groups of compounds were able to stimulate rabbit penile erection significantly. The following
APA, Harvard, Vancouver, ISO, and other styles
2

Reid, Anne Marie. "Raf-1 kinase inhibitor protein modulation of the cellular response to chemotherapeutic drugs and PDE5 inhibitors." Thesis, University of Glasgow, 2011. http://theses.gla.ac.uk/2497/.

Full text
Abstract:
RKIP was initially discovered as an endogenous inhibitor of the ERK and NF-κB pathways,and was also shown to prolong the activation of GPCRs via inhibition of the GRK2 protein. Now increasing evidence has linked RKIP to a metastases suppressing and chemo-sensitising role in cancer cells.The chemo-sensitising effect of RKIP was investigated in a colon carcinoma cell line using a variety of chemotherapeutic agents from conventional agents to newer targeted therapies. Initial results suggested that role of RKIP in the modulation of chemotherapeutic drug response was at the level of apoptosis; the
APA, Harvard, Vancouver, ISO, and other styles
3

Kurian, Stefanie [Verfasser]. "Effects of combination therapy of PDE5 inhibitor sildenafil and multikinase inhibitors sorafenib and sunitinib in NSCLC / Stefanie Kurian." Gießen : Universitätsbibliothek, 2015. http://d-nb.info/1076760546/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Santos, Filho Hilton Oliveira dos 1956. "Estudo clínico fase I de carbonato de lodenafila, um novo tipo de inibidor de fosfodiesterase 5 (PDE5), em voluntários saudáveis do sexo masculino = A phase I clinical trial of lodenafil carbonate, a new phosphodiesterase type 5 (PDE5) inhibitor, in healthy male volunteers." [s.n.], 2013. http://repositorio.unicamp.br/jspui/handle/REPOSIP/309461.

Full text
Abstract:
Orientador: Gilberto De Nucci<br>Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas<br>Made available in DSpace on 2018-08-22T19:42:28Z (GMT). No. of bitstreams: 1 SantosFilho_HiltonOliveirados_D.pdf: 1622141 bytes, checksum: 5f817cf4a04ee643bdf7e261e5861691 (MD5) Previous issue date: 2013<br>Resumo: Carbonato de Lodenafila é um novo tipo de inibidor de fosfodiesterase 5 (PDE5) utilizado no tratamento da disfunção erétil. O presente estudo foi realizado para avaliar a segurança, tolerabilidade e farmacocinética do carbonato de lodenafila após a administração
APA, Harvard, Vancouver, ISO, and other styles
5

Tavallai, Mehrad. "INTRODUCING NOVEL COMBINATORIAL TARGETED THERAPIES IN MULTIPLE TYPES OF CANCER." VCU Scholars Compass, 2016. http://scholarscompass.vcu.edu/etd/4088.

Full text
Abstract:
The cancers of liver, colon and breast are amongst the top five most prevalent and most fatal worldwide. As the Raf/MEK/ERK pathway is frequently deregulated in hepatocellular carcinoma (HCC), sorafenib, a Raf kinase inhibitor, became the first systemic therapy approved for the treatment of patients with HCC. However, sorafenib only produced modest effects with low response rates in the clinic. Similarly, regorafenib, which was approved for the treatment of metastatic colorectal cancer (CRC), has had a poor response rate in the clinic. Since phosphodiesterase type 5 has been reported to be ove
APA, Harvard, Vancouver, ISO, and other styles
6

Schaffner, Denise [Verfasser], and Irmgard [Akademischer Betreuer] Merfort. "Investigations of hepatic hemodynamics and alterations in the NO-cGMP pathway in an animal model of liver fibrosis / cirrhosis suggest PDE5 inhibitors as promising adjunct in portal hypertension therapy." Freiburg : Universität, 2018. http://d-nb.info/1189583216/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Megat, Salim. "Traitement de la douleur neuropathique : des antidépresseurs aux inhibiteurs de phosphodiestérases." Thesis, Strasbourg, 2014. http://www.theses.fr/2014STRAJ085/document.

Full text
Abstract:
Les antidépresseurs ont un effet antiallodynique qui dépend de la stimulation des récepteurs β2-adrénergiques. Ceux-ci stimulent la production d’adénosine monophosphate cyclique (AMPc) régulé par les phosphodiestérases de type 4 (PDE4). Nous avons ici étudié l’effet d’inhibiteurs de PDE (iPDE) sur la douleur neuropathique, grâce à des approches de pharmacologie comportementale chez la souris complétées par de l’imagerie calcium et des approches moléculaires. Nos résultats montrent un effet antiallodynique des iPDE4 et des iPDE5. L’action des iPDE4 est liée à une diminution d’expression du TNFα
APA, Harvard, Vancouver, ISO, and other styles
8

Clapham, John Christopher. "Characterisation and structural studies on dog heart cyclic nucleotide phosphodiesterase." Thesis, Birkbeck (University of London), 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.267913.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Xu, Chenjia. "A Novel in vitro PDE7 Inhibitor Inhibits IL-2 Gene Expression in Activated T Cells and Induces Apoptosis in a B-cell Line and Monocytic Cell Line." Thesis, Boston College, 2013. http://hdl.handle.net/2345/3935.

Full text
Abstract:
Thesis advisor: Thomas C. Chiles<br>Elevating intracellular cAMP levels can result in a wide range of anti-inflammatory effects and growth arrest and apoptosis in cancer cells, marking phosphodiesterases (PDEs) as potential targets for inflammatory diseases and cancer treatment. PDE7A is proposed to be a new therapeutic target for its ubiquitous expression in proinflammatory and immune cells. A Barbituric acid based compound, BC12 was identified as an in vitro PDE7 inhibitor in fission-yeast-based high-throughput screen. Analysis of this compound on the activation of Jurkat T lymphocytes, mous
APA, Harvard, Vancouver, ISO, and other styles
10

Joseph, Emlyn Clive. "Pathogenesis of arteriopathy induced by PDE III inhibitors in the rat and dog." Thesis, Queen Mary, University of London, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.307684.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "PDE5 inhibitors"

1

Porst, Hartmut. Erectile dysfunction. Edited by David John Ralph. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0103.

Full text
Abstract:
Erectile dysfunction (ED) can be improved by changing certain lifestyle factors such as sedentary lifestyle, unhealthy food, nicotine and alcohol abuse, or optimal management of risk factors/concomitant diseases causing or aggravating ED such as dyslipidaemia, hypertension, diabetes mellitus, depression, BPH/LUTS, or hypogonadism.First choice in the medical therapy of ED are PDE-5 inhibitors such as sildenafil, vardenafil, and tadalafil used p.r.n, or on a daily low-dose regimen regarding tadalafil, especially in patients suffering from ED and BPH/LUTS. Yohimbine and L-arginine may be consider
APA, Harvard, Vancouver, ISO, and other styles
2

Behrens, Frank, Michaela Koehm, and Michael J. Parnham. Synthetic DMARDs. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198737582.003.0028.

Full text
Abstract:
Synthetic disease modifying anti-rheumatic drugs (sDMARDs) are first line systemic treatment options for management of active psoriatic arthritis (PsA). Most of the compounds are used based on evidence from clinical trials in rheumatoid arthritis and from experience in routine care. Methotrexate is often recommended as the first choice within among sDMARDs, despite controversial or missing evidence of efficacy, according to experience over many years. Leflunomide, sulfasalazine, and cyclosporin are additional established options to treat PsA. The recently approved PDE4 inhibitor, apremilast, h
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "PDE5 inhibitors"

1

McAllister-Williams, R. Hamish, Daniel Bertrand, Hans Rollema, et al. "PDE5 Inhibitors." In Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_1542.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jackson, Graham. "The Hemodynamics of Phosphodiesterase-PDE5 Inhibitors." In Heart Disease and Erectile Dysfunction. Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-748-2_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Salonia, Andrea, Alberto Briganti, Andrea Gallina, and Francesco Montorsi. "The Utility of PDE5 Inhibitors After Radical Prostatectomy." In Sexual Function in the Prostate Cancer Patient. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-555-2_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kokkinos, Peter, Apostolos Tsimploulis, and Charles Faselis. "PDE5 Inhibitors for the Treatment of Erectile Dysfunction in Patients with Hypertension." In Erectile Dysfunction in Hypertension and Cardiovascular Disease. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-08272-1_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

McAllister-Williams, R. Hamish, Daniel Bertrand, Hans Rollema, et al. "PDE3 Inhibitors." In Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_1540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

McAllister-Williams, R. Hamish, Daniel Bertrand, Hans Rollema, et al. "PDE4 Inhibitors." In Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_1541.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

McAllister-Williams, R. Hamish, Daniel Bertrand, Hans Rollema, et al. "PDE Inhibitors." In Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_3466.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Padma-Nathan, Harin. "Sildenafil Citrate, the Classic PDE5 Inhibitor." In Oral Pharmacotherapy for Male Sexual Dysfunction. Humana Press, 2005. http://dx.doi.org/10.1385/1-59259-871-4:065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gresele, Paolo, Stefania Momi, and Emanuela Falcinelli. "Dipyridamole and PDE Inhibitors." In Platelets in Thrombotic and Non-Thrombotic Disorders. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-47462-5_86.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Drobnis, Erma Z., and Ajay K. Nangia. "Phosphodiesterase Inhibitors (PDE Inhibitors) and Male Reproduction." In Impacts of Medications on Male Fertility. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-69535-8_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "PDE5 inhibitors"

1

Contreras, Sonia, Jorge Oliver, Juliette Albert, Giancarlo Forte, Julio Cortijo, and Beatriz Ballester. "The combination of PDE4 and PDE5 inhibitors reduces YAP expression in IPF." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa1042.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Khatib, SY, and A. Badwan. "Bronchodilation Effects of PDE5 Inhibitors (Sildenafil & Ordonofil): Role of cGMP/cAMP-NO." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a2437.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hu, Jinwei, Julia Y. Ljubimova, Satoshi Inoue, et al. "Abstract 1447: PDE5 inhibitors increase trastuzumab transport for treatment of HER2-positive metastatic brain tumors." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1447.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Rui, In-Kiu Kwon, Sridhar Subbaramia, and Darren D. Browning. "Abstract 4421: PDE5 inhibitors suppress proliferation and augment the epithelial barrier by activating PKG2 in the colon." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4421.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Beretz, A., F. Lanza, A. Stierlé, and J.-P. Cazenave. "CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS PREVENT AGGREGATION AND SECRETION OF HUMAN PLATELETS BY RAISING CYCLIC AMP AND REDUCING CYTOPLASMIC FREE CALCIUM MOBILIZATION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643586.

Full text
Abstract:
Drugs that raise platelet cyclic AMP (cAMP) are potent inhibitors of platelet activation. We have studied the effects of 5 inhibitors of cyclic nucleotide phosphodiesterase (PDE) of different chemical structures (quercetin, Ro 15-2041, HL-725, cilostamide and MY-5445), which are all potent inhibitors of platelet function. The concentrations that inhibit by 50 % crude cAMP-PDE activity (IC50) from human platelets are: 0.06 μM(HL-725), 0.15 μM(Ro 15-2041 ), 0.23 μM(cilostamide), 6.9 μM(MY-5445) and 44.4 μM(quercetin). We measured on the same preparation of washed human platelets loaded with quin
APA, Harvard, Vancouver, ISO, and other styles
6

Yoneda, K., S. Togo, Y. Namba, et al. "The PDE5-Inhibitor Sildenafil Inhibits Fibroblast Chemotaxis." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5059.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Weisenberger, H., and W. Haarmann. "CORRELATION BETWEEN INHIBITION OF PLATELET PHOSPHODIESTERASES (PDEs) AND PLATELET FUNCTION TESTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643433.

Full text
Abstract:
A systematic investigation of over 100 PDE inhibiting pyrimidopyrimidines was performed regarding a possible correlation between influence on platelet function tests and inhibition of platelet PDEs. Basically, the compounds tested were congeners of Dipyridamole but lack substitution in position 6. The concentration necessary for a 50% inhibition of PDE activity in platelet homogenates ranged between 0.000045 and 35 μmoles/L.The inhibition of platelet PDEs was measured in freeze-thaw homogenates of human platelets using 3H-cAMP as substrate. Intraplatelet cAMP changes were measured by prelabell
APA, Harvard, Vancouver, ISO, and other styles
8

Takeda, K., Y. Shiraishi, J. Domenico, et al. "Combined Effects of the Phosphodiesterase Type 4 (PDE4) Inhibitor, Roflumilast, and the PDE5 Inhibitor, Tadalafil, in Allergen-Induced Airway Hyperresponsiveness (AHR)." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5717.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rheault, Tara, Thomas Bengtsson, and Kathleen Rickard. "Ensifentrine, a dual PDE3/PDE4 inhibitor, improves FEV1 regardless of smoking status or history of chronic bronchitis." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.4786.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Grant, P. G., A. F. Mannarino, and R. W. Colman. "REGULATION OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ACTIVITY IN PLATELETS BY PHOSPHORYLATION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642820.

Full text
Abstract:
Cyclic nucleotide phosphodiesterases (PDE) provide the only known pathway for the hydrolysis of cyclic nucleotides in cells and thus have the potential for modulating the effects of cAMP and cGMP on cells. In platelets a rise in intracellular cAMP levels inhibits platelet aggregation and secretion. Since cAMP exerts many of its effects through a cAMP-dependent kinase we questioned whether phosphorylation of cAMP PDE might be a mode for regulation of PDE activity in platelets. When platelets were incubated for 10 min with forskolin (100 μM) the level of cAMP rose at least 10-fold.When the low K
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "PDE5 inhibitors"

1

Are all PDE5 inhibitors the same? BJUI Knowledge, 2018. http://dx.doi.org/10.18591/bjuik.0470.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Medical management of priapism, with a focus on PDE5 inhibitors. BJUI Knowledge, 2016. http://dx.doi.org/10.18591/bjuik.0610.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'PDE5 inhibitors' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography